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Animal  models have been developed (1-4) in which established and dissemi- 
nated  tumors  can  be eradicated  by the  adoptive  transfer  of syngeneic  T  cells 
specifically immune to tumor-associated antigens.  These models have served as 
prototypes for understanding  how the immune system of a  tumor-bearing host 
might be manipulated to promote in vivo lysis of advanced tumors. Many factors 
necessary for  successful immunotherapy  have  now been  elucidated,  including 
the need for immune effector T  cells capable of persisting in the host (5, 6), the 
long time period required  for elimination  of all tumor cells by immune cells in 
vivo (5), and the importance of ablating suppressor cells, induced in the host by 
the growing tumor, which interfere with the expression of transferred immunity 
(3,  7).  Although  specific T  cell immunity is necessary for tumor eradication,  it 
has been difficult to determine which immunologic effector mechanism(s) must 
be operative in vivo for these transferred T  cells to be effective. 
Cytolytic T  cells (CTL) ~ can directly and immediately kill tumor cells in vitro. 
Adoptively  transferred  CTL  have  been  shown  to  prevent  the  outgrowth  of 
recently transplanted  tumors,  and  to contribute  to tumor elimination  in  some 
therapy settings (4,  8,  9);  the rejection of a  murine  sarcoma following transfer 
of immune T  cells has been correlated with the in vivo generation of CTL (10). 
Thus,  CTL  may be important  for the  elimination  of established disseminated 
tumors.  However, studies using purified functional  subsets of immune T  cells 
have  suggested  that  transfer  of the  noncytolytic  helper  T  cell  subset,  which 
presumably  can  induce  a  tumoricidal  delayed-type hypersensitivity (DTH)  re- 
sponse in  vivo, is necessary and  sufficient for tumor eradication  (11,  12).  This 
conclusion was supported by studies (13) suggesting that a similar DTH phenom- 
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enon  is  responsible  for  rejection  of allografts.  Since,  in  these  settings,  the 
transferred helper cells could also be amplifying CTL responses in vivo (11,  14), 
it  still  remains  unclear  whether  mechanisms  other  than  direct  tumor  lysis  by 
CTL in vivo are important in adoptive tumor therapy. Although this issue might 
theoretically be resolved most directly by the  in vivo infusion of T  cell clones 
with specific and restricted function, the results of therapy of syngeneic tumors 
with  such  clones  have,  to  date,  been  disappointing  (15-17).  The  therapeutic 
failures with T  cell clones might reflect problems of T  cell survival and homing 
in  vivo  (18,  19),  rather  than  reflecting  inadequate  or  inappropriate  effector 
function. 
Our studies have been designed to determine whether noncytolytic Lyt-1 +,2- 
cells can  effect eradication  of established  tumors  without  inducing  CTL.  We 
have  utilized  adoptive  chemoimmunotherapy  (ACIT)  models  in  which  mice 
bearing disseminated  tumors can be cured by combined treatment  with cyclo- 
phosphamide  (CY)  (which  has  both  direct  tumoricidal  activity and  can  ablate 
tumor-induced  suppressor  ceils  in  the  host  [5,  7]),  followed  by  transfer  of 
specifically immune T  cells (1, 20). Previous studies of ACIT using immunolog- 
ically intact mice as hosts have demonstrated  that  the adoptive transfer  of the 
immune Lyt-1 +,2- T  cell subset can achieve therapeutic results nearly as good as 
those obtained  with  unfractionated  T  cells (11).  The  transfer  of purified  Lyt- 
1+,2 -  T  cells ruled out participation  of donor CTL in tumor eradication,  but a 
potentially significant contribution by host-derived CTL could not be excluded. 
To eliminate the possibility of such a host contribution, we infused purified Lyt- 
1+,2 -  T  cells into T-deficient ATXBM  (adult,  thymectomized,  irradiated,  and 
T-depleted  bone-marrow  reconstituted)  B6  mice bearing disseminated  FBL-3 
leukemia.  However, even such T-deficient hosts contain  T  cell precursors with 
the potential to differentiate under certain conditions (14, 21). Therefore, donor 
cells were obtained from congenic B6/Thy-l.l  mice, which permitted both the 
phenotypic distinction and  the functional assessment of the tumor reactivity of 
transferred donor T  cells (Thy-1.1 +) from any residual or newly generated host 
T  cells (Thy-1.2+). The results demonstrate that immune Lyt-1 ÷,2- T  cells, which 
are not directly cytolytic to tumor cells, can recognize and mediate rejection of 
a disseminated tumor without the participation of CTL. 
Materials and Methods 
Mice.  C57BL/6  (H-2 b,  Thy-l.2;  denoted  B6)  mice,  breeding  pairs  of  congenic 
B6.PL(74NS)  (H-2  b,  Thy-l.1;  denoted  B6/Thy-l.1),  and  BALB/c  (H-2  d)  mice  were 
obtained from The Jackson Laboratory, Bar Harbor, ME. To prepare ATXBM hosts, 5- 
wk-old B6 mice were thymectomized, lethally irradiated (950 rad) 3 wk later, and injected 
intravenously  with B6 bone marrow cells that had been depleted of T cells by treatment 
with monoclonal  IgM anti-Thy-l.2 plus selected rabbit complement. These mice, used 4 
wk later, were killed at the end of the experiments to confirm the absence of Thy-1.2  + T 
cells. 
Cell Depletion and Fluorescence Analysis  With Monoclonal  Antibodies (mAb).  T cells were 
depleted  with  either  IgM  anti-Thy-l.2  or  IgG  anti-Lyt-2  mAb  plus  selected  rabbit 
complement. T cell phenotype was assessed on a fluorescence-activated  cell sorter and on 
a fluorescence microscope,  with cytocentrifuged preparations of cells double-labeled with 
combinations of fluorescein-conjugated anti-Thy-l.2, anti-Lyt-1,  or anti-Lyt-2  mAb and 
biotin-conjugated anti-Thy-l.1,  anti-Lyt-I  or anti-Lyt-2  (Becton  Dickinson  Monoclonal 1124  ERADICATION OF  DISSEMINATED  TUMOR  BY  Lyt-l+,2 -  T  CELLS 
Center Inc., Mountain View, CA) plus avidin-phycoerythrin kindly provided by Dr. Jeff 
Ledbetter of Genetic Systems Corporation, Seattle, WA. 
Assessment  of Class  I  and  Class  II  MHC  antigen  expression  was  performed  with 
commercially obtained monoclonal IgG anti-KbD  b (Australian  Monoclonal Development 
Pty. Ltd, New South Wales, Australia), and antibodies derived from hybridomas obtained 
from the American Type Culture Collection, Rockville, MD, including 25-9-3S, producing 
an IgM anti-lab; 34-5-8S, producing an IgG anti-Dd;  and MKD6, producing an IgG anti- 
Iad. Following labelling with these antibodies, cells were prepared for analysis on the cell 
sorter with the use of fluorescein-conjugated goat anti-mouse IgG or rat anti-mouse lgM 
(Becton Dickinson Monoclonal Center Inc., Mountain View, CA). 
Tumor.  FBL-3 is a Friend virus-induced erythroleukemia of B6 origin that has been 
subcloned in vitro, and maintained by serial intraperitoneal transplantation in syngeneic 
mice. Donor B6/Thy-l.1  mice were sensitized to FBL-3 in vivo by inoculation of three 
doses of 2  X  107 irradiated  FBL-3 intraperitoneally at 2-wk intervals, and the immune 
cells were obtained 2-4 wk later. This regimen has been shown (1, 20) to induce antigen- 
specific major histocompatibility complex (MHC)-restricted T  cell  immunity to FBL-3 
tumor in B6 mice (1,20). In vitro sensitization was performed in mixed lymphocyte tumor 
culture  as described  previously (11,  20).  Briefly, 6  X  106  responder spleen  cells were 
cultured for 5 d  in  12-well  tissue culture plates (Costar, Cambridge, MA) containing 30 
ml of supplemented  RPMI  1640  medium,  5%  fetal calf serum, and  either  1.5  x  10 6 
irradiated allogeneic stimulator spleen cells, or 0.3 x  106 irradiated FBL-3 tumor cells. 
For assessment of FBL expression of MHC antigens and target susceptibility following 
exposure to immune interferon (IFN),  FBL tumor cells were incubated for 24 h  with 
murine IFN-7 generated by recombinant DNA technology and kindly provided by Dr. 
Mike Shepard (Genentech Corporation, South San Francisco, CA), at concentrations of 2 
and  10 U/ml. The enhancement by IFN-~, of the expression of MHC antigens has been 
shown (22,  23) with other tumor cell  lines to be maximal following exposure to  1-2 U 
1FN-3, for 24 h. 
Adoptive Chemoimmunotherapy.  This assay, previously described in detail (1,  5, 6,  11), 
consists of treating mice suffering advanced disseminated FBL-3 leukemia with a combi- 
nation of chemotherapy and ado6Ptively transferred immune ceils. ATXBM B6 hosts were 
inoculated on day 0 with 5 X 10  FBL-3, and treated on day 5, after tumor dissemination 
had  occurred (5),  with  180  mg/kg CY  i.p.,  followed in  5  h  by adoptively transferred 
g6/Thy-1.1 donor cells. Studies with noncrossreactive tumors of B6 origin have demon- 
strated that the therapeutic efficacy of ACIT requires the transfer of specifically immune 
T  cells  (1,  20);  nonimmune  spleen  cells  have  no  therapeutic  activity  (11),  and  the 
magnitude of survival prolongation and rate of cure are proportional to the number of 
immune cells transferred (1, 24). 
In Vitro Detection of Antitumor Reactivity.  Cytolytic activity was determined, as previ- 
ously described,  by 4-h  incubation  of effector cells with  104  chromium-labelled FBL-3 
syngeneic tumor targets or concanavalin A-induced BALB/c allogeneic spleen cell blast 
targets (I 1, 20).  To assess interleukin 2 (IL-2) production in response to FBL-3, 5 X  10  6 
responder spleen cells were cultured with 5  ×  105 irradiated stimulator cells  in 48-well 
plates and supernatants were removed after 48 h. These supernatants were diluted and 
added  to 24-well plates containing CTLL-2 cells,  an IL-2-dependent T  cell line kindly 
provided by Dr.  Steve Gillis  (Immunex Corporation,  Seattle,  WA), and [3H]thymidine 
uptake was measured 24 h later, as previously described (25). 
Results 
Eradication  of Disseminated  FBL-3 in ATXBM Hosts  by  Treatment  with CY and 
Lyt-l+,2 -  Immune  T  Cells.  To  determine  whether  noncytolytic  T  ceils  are 
sufficient to  mediate complete eradication  of disseminated antigenic  leukemia, 
T  cell-deficient host mice were injected with a  lethal tumor dose,  then  treated 
with a  purified subpopulation of immune Lyt-l+,2 -  T  cells. On day 0, ATXBM 
host B6 mice were inoculated with 5  ×  106  FBL-3 cells. Some were then treated GREENBERG  ET  AL.  1125 
on day 5,  by which  time the  tumor had  disseminated  to peripheral blood and 
spleen (5). Untreated ATXBM hosts had a  median survival time of 10 d, which 
could be prolonged to 24 d  by treatment on day 5  with CY alone, but all mice 
in both groups died of progressive tumor growth (Fig. 1). Treatment of ATXBM 
mice with  107 immune cells alone on day 5 had no effect on survival, consistent 
with  previous studies  (5)  in  this  model,  showing  that  reduction  of the  tumor 
burden  by  treatment  with  CY  before  cell  transfer  is  necessary  to  detect  an 
antitumor effect. Tumor growth patterns similar to those demonstrated in these 
T-deficient hosts  were  observed  in  immunologicaily intact  B6  hosts.  Thus,  as 
previously published (1,  11),  untreated B6 hosts had a  median survival time of 
11 d, and treatment on day 5 with CY alone or CY plus 107 normal, nonimmune 
spleen cells prolonged median survival to 25 d  (data not shown). 
Treatment of ATXBM hosts on day 5 with CY plus 10 7 unfractionated spleen 
cells from B6/Thy-l.1  donors immune  to FBL-3 cured  11  of 12 mice (Fig.  1). 
The results of therapy of these ATXBM B6 mice (lacking host T  cells) with CY 
plus subpopulations of immune T  cells paralleled results seen (11) in the treat- 
ment of tumor-bearing immunocompetent hosts. Thus, treatment with CY plus 
107 cells functionally defined as  Lyt-l-,2  + (i.e., depleted of helper activity with 
anti-Lyt-1  and  complement)  had  only  a  minimal  antitumor  effect,  whereas 
therapy with CY plus Lyt-1 +,2- T  cells (i.e., depleted of CTL and CTL precursors 
by anti-Lyt-2 and complement) cured all  12 mice.  Mice were observed for 80- 
100 d  to be certain that the tumor had been completely eliminated by ACIT, 
and were then killed for analysis of the T  cell compartment. 
Analysis  of Splenic  T  Cells  in  ATXBM  Mice  Cured  of Disseminated  FBL-3  by 
ACIT.  The results of therapy implied that eradication of disseminated leukemia 
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FIGURE  1.  Therapy of ATXBM B6 hosts bearing disseminated FBL-3 leukemia. T-deficient 
ATXBM B6 hosts were inoculated with 5 × 106 FBL-3 cells intraperitoneally on day 0, then: 
left untreated (NO THERAPY); treated on day 5 with 107 immune spleen cells from congenic 
B6/Thy-l.1 donor mice previously sensitized to FBL-3 in vivo (IMMUNE CELLS ALONE); 
treated on day 5 with 180 mg/kg CY (CY ALONE); or treated on day 5 with CY plus 10  7 
immune B6/Thy-1.1 spleen cells. The immune cells were either used unfractionated (CY + 
Immune Cells), or following cell depletion with anti-Lyt-2 and complement (CY + Lyt-l+,2 - 
Immune Cells) or anti-Lyt-I and complement (CY + Lyt-l-,2 +  Immune Cells). 1126  ERADICATION  OF  DISSEMINATED  TUMOR  BY  Lyt-l+,2 -  T  CELLS 
required  neither donor nor host CTL.  To confirm  that CTL  were  indeed  not 
present,  splenic  T  cells  of cured  mice  were  analyzed  for both  CTL  phenotype 
and  function.  Thus,  spleen  cells,  obtained  from  ATXBM  B6  hosts  80-100  d 
after ACIT treatment for disseminated  FBL-3 leukemia, were labelled with mAb 
conjugated  for  fluorescence  analysis,  and  examined  in  vitro  for  immunologic 
reactivity.  ATXBM  B6 hosts cured by ACIT  with either unfractionated or Lyt- 
1+,2 -  T  cells from B6/Thy-l.1  donors contained 8-11%  donor Thy-l.1 + T  cells 
(Table  I).  Although  these  mice  were  usually devoid  of any host T  cells,  a  few 
mice contained  1-2%  Thy-l.2 + cells.  By comparison,  <1%  background fluores- 
cence  with  anti-Thy-l.2  was  detected  in  normal  B6/Thy-l.1  spleens,  and  22- 
28% Thy-1.2 + cells were detected in normal B6 spleens. ATXBM  hosts that had 
received  donor  cells  treated  with  anti-Lyt-2  and  complement  before  transfer 
contained  <1%  Lyt-2 +  spleen  cells,  as  compared  to  9-4%  in  hosts  receiving 
unfractionated  donor  cells,  and  4-7%  in the  spleens  of normal  donors.  Thus, 
most ATXBM  hosts cured of FBL-3  leukemia  by ACIT  with  Lyt-l+,2 -  T  cells 
contained no host-derived T  cells and no Lyt-2 + T  cells. 
Freshly obtained spleen cells from cured mice or mice immune to FBL-3 were 
not  directly  cytotoxic  to  either  FBL-3  tumor  or  allogeneic  spleen  cell  blasts. 
Therefore,  cytolytic activity  was  assessed  following  5-d  cultures  of spleen  cells 
grown in vitro with irradiated FBL-3 tumor, or allogeneic spleen cell stimulators. 
These  cultures  were  done  under conditions known  to generate  secondary,  but 
not  primary  responses  to  syngeneic  FBL-3  tumor,  and  primary  allogeneic  re- 
sponses (11,  20).  Cells obtained from ATXBM  hosts that had been treated with 
unfractionated  B6/Thy-1.1  donor spleen  cells  immune to FBL-3  could be stim- 
ulated to produce both tumor-specific and allospecific CTL (Table I). By contrast, 
TABLE  I 
Phenotype and Cytolytic Reactivity of Spleen Cells from ATXBM Hosts Cured by ACIT 
Phenotype of responder spleen cells'*  In vitro  Specific  lysis I 
Source of responder cells*  stimulator| 
Thy-l.2  +  Thy-l.l ÷  Lyt-I +  Lyt-2  +  FBL-3  BALB/c 
%  % 
B6/Thy-l.l~ti-vBL-3 anti-L),t-2  B6  FBL-3  2  0 
0-2  8-10  8-11  <1  BALB/c  0  0 
(ATXBM) 
FBL-3  41  4 
B6/Thy- 1. lam~vBt.s  ---' B6 (ATXBM)  0-2  8-11  8-12  2-4  BALB/c  2  33 
FBL-3  42  2 
B6/Thy- 1. I anti-Val.-S  <1  22-26  21-25  4-7  BALB/c  0  25 
FBL-3  1  1 
B6/Thy- 1.1  < 1  21-26  20-25  4-6  BALB/c  1  26 
* Responder spleen cells were obtained on days 80-100 from the cured B6 (ATXBM)  hosts (described in Fig. 1) that had been treated 
with either unfractionated  spleen cells  from immune  B6/Thy-l.1  donors [B6/Thy-l.l~ti-Fm..s--*  B6 (ATXBM)],  or donor cells  de- 
anti-L),t-2 
pleted of Lyt-2  + T cells LB6/Thy-i.I  ......  B6 (ATXBM)J.  O  ..... pond  .... U  ...... btained fr  .......  I B6/Zhy- 
1.1 donors or donors sensitized  to FBL-3 in vivo (Bf/Thy-I.I,~tI-FBL-S). 
* Spleen  cells  were  labelled  with  conjugated  mAb.  For  analysis  of T  cell  subsets,  two-color  fluorescence  was  performed  with 
fluoresceinated  anti-Lyt-1  or anti-Lyt-2  and phycoerythrin-avidin  with blotinylated  anti-Thy-l.1  Data  is presented as the range of 
percent positive  cells  from six spleens. 
i Spleen cells  were cultured for 5 d with irradiated  syngeneic  FBL-3  tumor cells or allogeneic  BALB/c spleen cell  stimulators. 
I Cytolytic  activity  was tested  in  a  4-h  chromium-release  assay  with  labelled  FBL-3  or BALB/c  spleen  blast  targets  at  an  effec- 
tor/target ratio of 20:1. The results  represent the means of triplicate  wells from six experimental groups. GREENBERG ET  AL.  1127 
cultures of cells from ATXBM hosts that had been cured by therapy with Lyt- 
2+-depleted donor cells failed to  lyse either target.  Control cultures of spleen 
cells  from  normal  mice  primed  in  vivo to  FBL-3  contained  CTL  reactive to 
FBL-3, whereas no CTL reactive with FBL-3 tumor were generated in spleens 
from normal  unprimed mice.  Thus, ATXBM  hosts cured by therapy with CY 
plus Lyt-l+,2  -  donor T  cells contained no Lyt-2  ÷ cells,  by phenotypic analysis, 
and no tumor-reactive or alloreactive CTL, by functional analysis. 
The ability of the persistent donor noncytolytic T  cells to respond to FBL-3 
tumor was assessed by measuring production of the lymphokine, IL-2, following 
in  vitro stimulation  (Table  II).  Spleen  cells  from  ATXBM  hosts  treated  with 
either Lyt-2-depleted, or unfractionated donor cells immune to FBL-3 produced 
IL-2  in  response  to  stimulation  by  FBL-3.  The  levels of IL-2  detected  after 
stimulation of the cells, which were obtained from cured mice, was higher than 
that  detected  from  cells  obtained  directly  from  primed  donor  mice,  possibly 
reflecting  further  expansion  of the  antigen-reactive  cell  population  following 
transfer  into  a  tumor-bearing  animal  (26).  Unprimed  cells  did  not  generate 
measurable amounts of IL-2 in response to FBL-3 (data not shown), consistent 
with the difficulty in generating a primary in vitro cytotoxic response to FBL-3 
(Table I). Thus, ATXBM B6 host mice, cured of disseminated FBL-3 by ACIT 
with immune Lyt-1 +,2- donor cells, contained no phenotypic or functional CTL 
against  FBL-3, but did contain donor cells capable of secreting lymphokines in 
response to the tumor. 
Analysis of  MHC Antigen Expression  on FBL-3 Tumor Cells Following Exposure  to 
IFN-%  Although Lyt-l+,2  -  T  cells generally recognize antigens in the context 
of class II MHC determinants expressed on antigen-presenting cells and perform 
noncytolytic functions, some Lyt-1 +,2- T  cells can act as CTL restricted to targets 
expressing  class  II  antigens.  FBL-3  is  an  erythroleukemia that  expresses  only 
TABLE  II 
Tumor-induced Lymphokine Production by Spleen Cells  from ATXBM Hosts Cured by ACIT 
IL-2 generation culture* 
Source of responder cells 
Supernatant-induced proliferation of 
CTLL-2 at dilutions of:* 
Stimulator  1:2  1:8  1:32 
FBL-3  9,506 
B6/Thy-  1.1 a.ti-VBL-S  anti-Lyt-2 B6  B6  610 
(ATXBM)  48,896 
FBL-3  14,610 
B6/Thy-I.la,,i.FBL_S--~B6(ATXBM)  B6  2,199 
5,986  3,972 
1,430  2,124 
44,556 
8,358 
2,338 
41,848 
4,265 
2,731 
412,411  46,020  41,534 
FBL-3  3,627  1,729  1,544 
B6/Thy-I.I~,ti-FBL.S  B6  1,859  1,544  2,150 
41,768  4175  4 -606 
* Responder spleen cells, as designated in Table I, were incubated for 48 h with irradiated syngeneic 
stimulators, FBL-3 cells, or spleen cells, and the culture supernatant was harvested. 
* An IL-2-dependent T cell line (CTLL-2) was incubated for 24 h with culture supernatants at the 
denoted dilutions, and incorporation of [3H]thymidine was measured. The results represent the 
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class I and no class II antigens (27).  However, IFN-?, a lymphokine known to be 
secreted by immune Lyt-1 +,2- T  cells in response to stimulation by antigen (28), 
has  been  shown  to  induce  and  increase  the  expression  of class  II antigens  on 
tumor cells (22, 23). Thus, CTL activity might still be necessary in tumor therapy 
if the Lyt-l+,2 -  T  cells responding to FBL-3 antigens induce  Ia antigen expres- 
sion on FBL-3 as a consequence of the secretion of IFN-3', and then function as 
class II-restricted CTL. Therefore, the expression of la  b on FBL-3 tumor cells 
following exposure to IFN-y was assessed. 
The sensitivity and specificity of labelling with mAb against H-2  b antigens was 
demonstrated with B6 and BALB/c spleen cells.  B6 spleen cells reacted with an 
mAb that recognizes a  determinant on class I  K b and D b antigens (Fig.  2B); the 
non-T  cell  subpopulation  reacted  with  an  mAb against  Iab (Fig.  2A).  Studies 
with H-2  d BALB/c spleen ceils and antibodies against Iad and D d confirmed the 
haplotype specificity of these previously well-characterized mAb (data not shown). 
FBL-3 tumor cells were labelled either directly, or after incubation  for 24  h 
with 2  U/ml recombinant routine  IFN--r. This dose was selected because it bad 
been shown (22,  23) to induce maximal expression of Ia antigens and  enhance 
expression  of K  and  D  antigens  in  other  tumor cell  lines.  FBL-3  cells reacted 
with  the  antibody against  K b and  D b,  and  the  level of antigen  expression  was 
increased  if  the  tumor  had  been  cultured  with  IFN-'y  (Fig.  2D).  However, 
FBL-3 cells did  not  react with  antibody against  Ia  b,  either  before or following 
the incubation with IFN-y (Fig. 2 C). Thus, exposure of FBL-3 to IFN-3, resulted 
in enhanced expression of class I antigens, but failed to induce expression of the 
class IIIa b determinants. 
Analysis of Splenic  T Cells in ATXBM Mice During the Period of Tumor Rejection 
by ACIT.  The lack of class II antigen expression by FBL-3, and the absence of 
o 
o 
~ 
Ia b 
(~  FBL- q<Ia  b 
.'..  . 
(~)B6  spleen cells-~KbD  b 
Fluorescence Intensity  (log 10 ) 
FIGURE 2.  MHC antigen  expression on  B6  spleen cells and FBL tumor cells. Cells were 
in  b  b  • cubated  with either mAb against la  (~la) or  KbD  b (e~KbDb), followed by labelling with a 
fluorescein-conjugated second step reagent  reactive with the mAb, then analyzed on a fluo- 
rescence-activated cell sorter• To assess the influence of IFN-y on MHC antigen expression 
by FBL-3, tumor cells were cultured  for 2't h before labelling, either in medium alone, or in 
the presence of 2 U/ml recombinant  IFN-% Unlabelled cells are represented  by the dotted 
lines ( ..... ), labelled cells by the solid lines (  ) and IFN-'r-treated and labelled cells by the 
dashed lines (  ..... ). GREENBERG  ET  AL.  1129 
Lyt-2  + CTL  in ATXBM  hosts that had been cured of FBL-3 by ACIT  with Lyt- 
1+,2 -  T  cells imply that T  cells directly cytolytic to tumor  are not necessary for 
tumor  eradication.  However,  the  functional  studies  performed  in  cured  mice 
would have missed any short-lived T  cells having direct cytolytic activity and that 
might  have  made  an  important  contribution  during  the  30-d  period  following 
ACIT  that is necessary for complete tumor elimination (5). Therefore,  ATXBM 
B6 host mice were ACIT-treated  on day 5, and T  cell function  was assessed on 
days  16,  26,  and  30.  Donor  cells depleted  of Lyt-2  ÷ T  cells contained  no  CTL 
reactive  to  FBL-3  nor  to  allogeneic  targets  before  transfer  (Table  III),  and 
ATXBM  hosts that received these cells contained no CTL  during  the period of 
tumor  eradication by immune  cells. By contrast, ATXBM  B6 hosts treated with 
unfractionated  donor  cells contained  both  tumor  and  alloreactive CTL.  The 
pattern  of cytolytic reactivity against  FBL-3  was qualitatively unchanged  if the 
tumor  target  was  preincubated  with  IFN-%  consistent  with  the  failure  of this 
lymphokine to induce expression of class II molecules on  FBL-3 (Fig. 2).  Thus, 
TABLE  III 
Cytolytic Reactivity of Spleen Cells from ATXBM Hosts During Period of Tumor Eradication 
by ACIT 
Day donor  Specific lysis  t 
cells ob-  In vitro 
tained  stimula-  FBL-3 +  FBL-3 + 
Donor responder cells*  from B6  to~  FBL-3  2 U  10 U 
(ATXBM)  IFN-3,  IFN-~, 
host 
BALB/c 
% 
FBL  18  17  20  0 
B6/Thy- 1.1 anti-FBL-3  BALB/c  1  0  0  18 
(B6/Thy 1.1 ~.ti.VSL.s)anti-  FB  L  2  1  0  0 
Lyt-2  BALB/c  0  1  0  0 
B6/Thy- 1.1 a,ti-FBL-~  16  FBL  NT  13  13  NT 
(B6/Thy- 1.1 a.ti_VBL.s)anti-  16  FBL  NT  2  1  NT 
Lyt-2 
B6/Thy-1.1 ~,ti-FBL-3  26  FBL  15  34  35  0 
(B6/Thy-1.1 a,ti.FSL.3)anti-  26  FBL  0  1  3  0 
Lyt-2 
FBL  31  30  32  0 
B6/Thy- I. 1  anti-F~.L-3  30  BALB/c  2  3  4  26 
(B6/Thy-1.1 a.ti_FBL.~)anti-  30  FBL  4  1  1  0 
Lyt-2  BALB/c  3  2  1  2 
* Responder spleen cells were obtained either before adoptive transfer from B6/Thy-l.1  donors 
immune to FBL-3; or they were obtained on days 16, 26, or 30 from B6 (ATXBM) hosts bearing 
disseminated FBL-3 that had been treated on day 5 with CY and 107 adoptively  transferred immune 
donor B6/Thy-1.1 spleen cells. The immune donor spleen cells were either used unfractionated or 
were depleted of Lyt-2  + T cells before direct testing or adoptive transfer. 
* Spleen cells were cultured for 5 d with irradiated syngeneic FBL-3 tumor or allogeneic BALB/c 
spleen cell stimulators. Due to low cell yields on days 16 and 26, responders were cultured with 
only tumor stimulators. 
0 Cytolytic activity was tested in a 4-h chromium-release assay at an effector/target ratio of 20:1. 
Targets were prepared as previously described, or after 24 h incubation with recombinant INF-~, 
at 2 or l0 U/ml. Due to low cell yields on day 16, effectors were tested only against IFN-treated 
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mice  being  cured  of disseminated  FBL-3  by  ACIT  with  Lyt-l+,2  -  T 
contained no tumor-reactive CTL during the period of tumor elimination. 
cells 
Discussion 
These studies demonstrate that adoptively transferred noncytolytic Lyt-l÷,2  - 
T  cells  that are immune to tumor-associated antigens can, in conjunction with 
CY, mediate rejection of a disseminated tumor in T-deficient ATXBM hosts, a 
setting in which neither donor nor host CTL should be available to participate 
in in vivo tumor lysis. To rule out the possibility that there had been incomplete 
cellular depletion, or that CTL precursors from ATXBM hosts had differentiated 
in vivo in the presence of antigen and lymphokines produced by helper T  ceils 
(14,  21),  the  treated  animals  were  examined  for  CTL  by  phenotypic  and 
functional analysis. The  results  showed that spleen  cells  from ATXBM  hosts 
cured by therapy with CY and transferred Lyt-l+,2  -  T  cells contained neither 
Lyt-2  + T  cells nor CTL that could lyse FBL-3 tumor cells. Thus, the transferred 
T  cells promoted tumor eradication either by inducing a DTH response, or by 
augmenting B  cell  antibody production. Although studies in which B  cell re- 
sponses have been suppressed or eliminated will be necessary to determine the 
extent to which antibody responses can contribute to tumor eradication, serother- 
apy has been ineffective in this model, and infusions of even very high titer mAb 
in similar models have produced only minimal effects in the therapy of advanced 
tumors (29,  30).  Therefore, it is likely that a  DTH cellular immune response, 
rather  than  a  humorai  response,  is  critical  for  tumor  eradication  following 
adoptive therapy. 
The in vivo efficacy of the DTH effector mechanism in the rejection of viable 
nonmalignant cells has been demonstrated in studies with skin allografts. Adop- 
tive transfer of immune, alloreactive Lyt-l+,2  -  T  cells  can induce rejection of 
skin  allografts in  ATXBM  hosts  (13,  14).  Initial studies correlated this graft 
rejection with the capacity of the noncytolytic Lyt-1 +,2- T cells to induce a DTH 
response to the alloantigens (13). Since subsequent studies (21) in ATXBM hosts 
suggested that the transferred alloreactive helper T  cells  might be capable of 
inducing differentiation of host prethymic CTL precursors in vivo, the potential 
importance of CTL in graft rejection in this model was reexamined (14). Analysis 
of the T  cell compartments of ATXBM mice that had rejected allografts after 
transfer of Lyt-l+,2  - T  cells revealed that many mice did, in fact, contain Lyt-2  + 
CTL of host origin.  However, several  mice were identified that had  rejected 
tbeir grafts, but contained no CTL (14).  Thus, it would appear that allograft 
rejection can be accomplished via a DTH mechanism, without the participation 
of CTL. We used a similar analysis to demonstrate the potential importance of 
DTH responses in the rejection of rapidly growing syngeneic tumors. In most, 
but not all mice cured of tumor, we found only donor-derived T  cells,  and no 
evidence  that  tumor-reactive  CTL  of host  origin  had  been  induced  by  the 
transferred helper cells. The absence of demonstrable CTL in our tumor therapy 
model, as  compared to  the  more  frequent detection of CTL  in  the allograft 
rejection model, may reflect the fact that the ATXBM hosts were treated with a 
lympholytic dose of CY  before transfer of immune cells  (31),  and/or a  lower GREENBERG  ET  AL.  1131 
frequency of CTL precursors reactive to the syngeneic tumor as compared to 
aliogeneic cells. 
FBL-3 is an erythroleukemia that expresses class I MHC antigens but does not 
express the necessary class II restricting elements for direct recognition by the 
T  cell receptor of Lyt-l+,2 - T  cells. Therefore, lysis of FBL-3 tumor by immune 
Lyt-1 +,2- T  cells must proceed via mechanisms other than direct cell-cell contact 
between  lymphocytes  and  the  tumor.  Potentially,  macrophages  may  process 
tumor  antigens  and  then  present  them  to  Lyt-l+,2 -  cells  in  the  context  of 
class II MHC products. The Lyt-l+,2 -  ceils may then secrete lymphokines, such 
as  IFN-y,  macrophage-activating  factor,  and/or  lymphotoxin,  that  promote 
tumor lysis via alternative effector pathways. Recent studies from our laboratory 
have demonstrated that specific stimulation of T  cells immune to FBL-3 results 
in secretion of a  macrophage-activating  factor that  renders previously nonlytic 
macrophages tumoricidai  to FBL-3 in  vitro (unpublished  results).  Similar  mac- 
rophage-activating  factors, such as IFN-y, are produced by specific stimulation 
of helper T  cell clones reactive to an antigenically related lymphoma, MBL (28). 
Our  studies  do  not  suggest  that  CTL  cannot  function  in  the  therapy  of 
disseminated FBL-3 leukemia, but rather that CTL may not be necessary in this 
setting.  Indeed,  it seems likely that  there should be conditions under  which T 
cells  directly  cytolytic  to  tumor  can  have  therapeutic  activity.  As  examples, 
rejection of an established fibrosarcoma has been shown (10) to correlate with 
the in vivo generation  of CTL reactive to the tumor, and the capacity to reject 
syngeneic solid tumors  has been enhanced  by the  infusion of CTL along with 
nonlytic cells (4). The efficacy of CTL in therapy may depend on such factors as 
the nature of the tumor and the target antigens,  the location of the tumor cells 
in the host, and whether the CTL must persist in the host and home to tumor 
sites.  CTL  may prove  to  be more  effective when  infused proximal  to a  solid 
tumor  mass  than  if  infused  systemically  in  the  treatment  of a  disseminated 
leukemia. However, regardless of the relative or potential contributions of CTL 
in some settings,  our results emphasize the importance  of effector mechanisms 
induced by noncytolytic T  cells. 
With improved means of selecting and growing reactive T  cells, an understand- 
ing of the  principles  of successful adoptive  transfer  of immunity  may assume 
increasing  importance.  This  study demonstrates  that,  in conjunction  with  CY, 
transferred  Lyt-l+,2 -  T  cells  can  eradicate  disseminated  tumors  in  ATXBM 
hosts. As observed with therapy of disseminated FBL-3 in immunoiogically intact 
mice,  immune  cells did not have a  significant  effect unless the tumor-bearing 
hosts were treated  with  CY before cell  transfer  (11).  CY can  potentially  both 
reduce the tumor burden by a direct tumoricidal effect (5), and ablate suppressor 
cells that  may be induced  in the host by the growing tumor and which inhibit 
the transfer of immulaity (7).  Since ATXBM hosts lack these suppressor T  cells 
(3,  7),  it  is  likely  that  the  large  burden  of the  FBL-3  tumor  interferes  with 
expression  of transferred  immunity.  Such interference  may not simply reflect 
infusion of an inadequate dose of lymphocytes, since much larger cell doses and 
multiple  infusions  of cells have  also been  ineffective (unpublished  results).  In 
addition to producing a large and rapidly increasing number of potential targets 
in  vivo,  the  large  tumor  mass  also  may  be  secreting  suppressor  factors  (32), 1132  ERADICATION  OF  DISSEMINATED TUMOR BY  Lyt-l+,2  -  T  CELLS 
presenting excess antigen that directly inhibits the expression of antigen-specific 
reactivity by effector cells  (33),  and/or inducing suppressor  cells  in the trans- 
ferred population, which subsequently suppress immunity. This last explanation 
is  supported  by  evidence  (34,  35)  for  the  role  of  Lyt-l+,2  -  T  cells  in  the 
suppression of DTH and transferred tumor immunity. Moreover, such suppres- 
sor cells  have been  shown (35)  to develop during, and then interfere with an 
ongoing antitumor response. Thus, full expression of transferred immunity may 
require a greater understanding of immunoregulatory pathways and appropriate 
perturbation of those pathways that develop after cell transfer. 
Summary 
The ability of noncytolytic Lyt-l+,2  -  T  cells  immune to FBL-3 leukemia to 
effect eradication  of disseminated FBL-3  was  studied.  Adult  thymectomized, 
irradiated, and T-depleted bone marrow-reconstituted (ATXBM) B6 hosts were 
cured of disseminated FBL-3 by treatment with  180  mg/kg cyclophosphamide 
(CY)  and  adoptively  transferred  Lyt-l+,2  -  T  cells  obtained  from  congenic 
B6/Thy-l.l donors immune to FBL-3. Analysis of the T  cell compartment of 
ATXBM hosts treated and rendered tumor-free by this therapy revealed that 
the only T  cells  present in the mice were donor-derived Lyt-l+,2  -  T  cells.  In 
vitro stimulation of these T  cells with FBL-3 tumor cells,  which express class I 
but no class II major histocompatibility complex antigens, induced lymphokine 
secretion, but did not result in the generation of cytotoxic T  lymphocytes (CTL). 
Thus, in a  setting in which mice lack Lyt-2  ÷ T  cells,  and in which no CTL of 
either host or  donor origin could be  detected, immune Lyt-l+,2  -  T  cells,  in 
conjunction with  CY,  mediated eradication of a  disseminated leukemia. The 
results suggest that delayed-type hypersensitivity responses induced by immune 
T  cells represent a potentially useful effector mechanism for in vivo elimination 
of disseminated tumor cells. 
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